ES2143793T3 - Utilizacion de la resistencia magnetica nuclear para identificar ligandos con biomoleculas blanco. - Google Patents

Utilizacion de la resistencia magnetica nuclear para identificar ligandos con biomoleculas blanco.

Info

Publication number
ES2143793T3
ES2143793T3 ES96940448T ES96940448T ES2143793T3 ES 2143793 T3 ES2143793 T3 ES 2143793T3 ES 96940448 T ES96940448 T ES 96940448T ES 96940448 T ES96940448 T ES 96940448T ES 2143793 T3 ES2143793 T3 ES 2143793T3
Authority
ES
Spain
Prior art keywords
ligand
target molecule
biomolecules
white
nuclear magnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940448T
Other languages
English (en)
Other versions
ES2143793T5 (es
Inventor
Stephen W Fesik
Philip J Hajduk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of ES2143793T3 publication Critical patent/ES2143793T3/es
Application granted granted Critical
Publication of ES2143793T5 publication Critical patent/ES2143793T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN PROCESO PARA IDENTIFICAR COMPUESTOS QUE SE UNEN A UNA MOLECULA DIANA ESPECIFICA. EL PROCESO INCLUYE LOS PASOS DE: A) GENERAR UN PRIMER ESPECTRO DE CORRELACION BIDIMENSIONAL 15 N/ 1 H NMR DE UNA MOLECULA DIANA ETIQUETADA 15 N; B) EXPONER LA MOLECULA DIANA E TIQUETADA A UN COMPUESTO QUIMICO O A UNA MEZCLA DE COMPUESTOS QUIMICOS; C) GENERAR UN SEGUNDO ESPECTRO DE CORRELACION BIDIMENSIONAL 15 N/ 1 H NMR DE LA MOLECULA DIANA ETIQUETADA QUE SE HA EXPUESTO A UN COMPUESTO O A UNA MEZCLA DE COMPUESTOS EN EL PASO (B); Y D) COMPARAR EL PRIMER Y SEGUNDO ESPECTRO DE CORRELACION BIDIMENSIONAL 15 N/ 1 H NMR PARA DETERMINAR LAS DIFERENCIAS ENTRE EL PRIMER Y SEGUNDO ESPECTRO MENCIONADOS, DIFERENCIAS QUE IDENTIFICAN LA PRESENCIA DE UNO O MAS COMPUESTOS QUE SON LIGANDOS QUE SE HAN UNIDO A LA MOLECULA DIANA.
ES96940448T 1995-11-14 1996-11-13 Utilizacion de la resistencia magnetico nuclear para identificar ligandos con biomoleculas blanco. Expired - Lifetime ES2143793T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules
US555691 1995-11-14

Publications (2)

Publication Number Publication Date
ES2143793T3 true ES2143793T3 (es) 2000-05-16
ES2143793T5 ES2143793T5 (es) 2008-03-01

Family

ID=24218250

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940448T Expired - Lifetime ES2143793T5 (es) 1995-11-14 1996-11-13 Utilizacion de la resistencia magnetico nuclear para identificar ligandos con biomoleculas blanco.

Country Status (13)

Country Link
US (2) US5698401A (es)
EP (2) EP0866967B2 (es)
JP (1) JP3032301B2 (es)
AT (2) ATE189063T1 (es)
AU (1) AU701810B2 (es)
CA (1) CA2237343C (es)
DE (2) DE69606324T3 (es)
DK (1) DK0866967T4 (es)
ES (1) ES2143793T5 (es)
GR (1) GR3032361T3 (es)
IL (2) IL155988A (es)
PT (1) PT866967E (es)
WO (1) WO1997018471A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
FI982069A7 (fi) * 1996-03-29 1998-11-10 Lawrence Berkeley Nat Laboratory NMR:n ja MRI:n tehostaminen hyperpolaroitujen jalokaasujen läsnä olles sa
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
JP2002505004A (ja) * 1997-06-13 2002-02-12 バーテックス ファマシューティカルズ インコーポレイテッド 薬剤核を同定する方法
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6288234B1 (en) * 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US7501236B1 (en) * 1998-12-30 2009-03-10 Ge Healthcare Limited NMR spectroscopic in vitro assay using hyperpolarization
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
AU6115300A (en) * 1999-07-19 2001-02-05 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
CA2383559A1 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
JP2003510608A (ja) * 1999-09-29 2003-03-18 スミスクライン・ビーチャム・コーポレイション 標的生体分子と相互作用する化合物を同定するための一次元および多次元核磁気共鳴の使用法
CA2400094A1 (en) * 1999-09-29 2001-04-05 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
MXPA02008253A (es) * 2000-02-25 2002-11-29 Wyeth Corp Metodos de diseno de farmacos basados en la estructura usando em/rmn.
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
JP5129424B2 (ja) 2000-09-27 2013-01-30 ユニヴェルシテイト レイデン リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
CA2432924A1 (en) * 2000-12-21 2002-06-27 Triad Therapeutics, Inc. Sea-trosy and related methods
MXPA03005777A (es) * 2000-12-22 2005-02-14 Johnson & Johnson Derivados de triazol diaminas sustituidos como inhibidores de cinasa.
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
WO2002097450A2 (en) * 2001-05-30 2002-12-05 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003040400A2 (en) * 2001-11-06 2003-05-15 Message Pharmaceuticals, Inc. Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
WO2003091700A2 (en) * 2002-03-26 2003-11-06 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
US20060154323A1 (en) * 2002-06-10 2006-07-13 Prospect Pharma Method for obtaining dynamic and structural data pertaining to proteins and protein/ligand complexes
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) 2002-11-29 2002-11-29 Amersham Health As Metode
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
US7964534B2 (en) * 2003-03-13 2011-06-21 Triad Liquidating Company, Llc Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
WO2004092727A2 (en) * 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
WO2004095028A1 (ja) * 2003-04-23 2004-11-04 Olympus Corporation 受容体に結合可能な物質をスクリーニングする方法
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20070275442A1 (en) * 2003-10-07 2007-11-29 Prospect Pharma Side Chain Deuterated Amino Acids Methods Of Use
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
US7904252B2 (en) * 2003-11-28 2011-03-08 Hitachi, Ltd. Method for measuring a structural change in a protein
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP1794324A4 (en) 2004-09-20 2010-04-14 Wisconsin Alumni Res Found NONLINEAR SPECTROSCOPIC PROCEDURES FOR IDENTIFICATION AND DESCRIPTION OF MOLECULAR INTERACTIONS
JPWO2006082963A1 (ja) * 2005-02-07 2008-06-26 三菱化学株式会社 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
JPWO2012108297A1 (ja) * 2011-02-07 2014-07-03 国立大学法人神戸大学 Ｒａｓ部分ポリペプチド含有水溶液及びＲａｓ機能阻害剤のスクリーニング方法
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
IL305285A (en) 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7034791A (en) * 1989-12-29 1991-07-24 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
DK0593618T3 (da) * 1991-06-27 1998-11-23 Genelabs Tech Inc Screeningsassay til påvisning af DNA-bindende molekyler

Also Published As

Publication number Publication date
MX9803810A (es) 1998-09-30
EP0981049B1 (en) 2004-03-10
AU7732896A (en) 1997-06-05
PT866967E (pt) 2000-04-28
IL155988A (en) 2005-07-25
DE69606324D1 (de) 2000-02-24
ATE261581T1 (de) 2004-03-15
DK0866967T4 (da) 2007-12-10
US5698401A (en) 1997-12-16
WO1997018471A1 (en) 1997-05-22
CA2237343A1 (en) 1997-05-22
DE69606324T2 (de) 2000-07-06
AU701810B2 (en) 1999-02-04
EP0866967B2 (en) 2007-08-08
EP0866967A1 (en) 1998-09-30
ATE189063T1 (de) 2000-02-15
DK0866967T3 (da) 2000-06-26
EP0981049A1 (en) 2000-02-23
CA2237343C (en) 2009-01-20
IL123923A (en) 2005-07-25
DE69631842D1 (de) 2004-04-15
JP3032301B2 (ja) 2000-04-17
US5804390A (en) 1998-09-08
IL155988A0 (en) 2003-12-23
JPH11513498A (ja) 1999-11-16
ES2143793T5 (es) 2008-03-01
DE69606324T3 (de) 2008-02-07
EP0866967B1 (en) 2000-01-19
GR3032361T3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ES2143793T3 (es) Utilizacion de la resistencia magnetica nuclear para identificar ligandos con biomoleculas blanco.
ES2159056T3 (es) Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco.
DE59007200D1 (de) Verfahren zur Bestimmung eines Analyten.
CA2653517A1 (en) Process of designing a drug
PT839152E (pt) Bibliotecas combinatorias de compostos bioquimicos marcados e metodos para as produzir.
ATE248859T1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
DE69637930D1 (de) Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität
FI913891A7 (fi) Uusi monoklonaalinen vasta-aine uutta antigeenia vastaan, joka liittyy ihmisen kasvaimiin
DE69210911D1 (de) Fahrzeug, durch Verwendung magnetischer Kräfte geeignet zur dreidimensionalen Fortbewegung
EP0654766A3 (en) Process for analyzing data defining an image.
EP1076264A3 (en) Multi-channel grating interference alignment sensor
FR2657695B1 (fr) Procede de pointe de surfaces dans un volume 3d.
FR2690997B1 (fr) Système optoélectronique d'acquisition de cible à très grand champ.
EP0638816A3 (en) Measurement of the flow by a difference method of the complex image values by means of magnetic resonance.
NO980292D0 (no) Fremgangsmåte for bestemmelse av vandretidsfelter for seismiske data, ved hjelp av parallelle prosessorer
DE69100611D1 (de) Kompakte Sonde für die magnetische Kernresonanz.
FI900498A7 (fi) Menetelmä vasta-aineen tuottamiseksi tautipatogeenia vastaan
DE59107957D1 (de) Verfahren für die zweidimensionale Kernresonanzspektroskopie
FR2669137B1 (fr) Procede de reconnaissance d'objets tridimensionnels par analyse d'image.
DE69006794D1 (de) Elektrofotografisches Bilderzeugungsverfahren.
FI925081A7 (fi) Menetelmä antigeenispesifisen, korkea affiniteetti monokloonisen vasta -aineen valmistamiseksi
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
BR1100583A (pt) R6-5-d6, um anticorpo o qual liga a molécua-1 de adesão intercelular
BR8906338A (pt) Aparelho medidor da compactacao de solos para fins agricolas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 866967

Country of ref document: ES